3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
6
Recruiting
2
Active not recruiting
2
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Nasopharyngeal Carcinoma
4
Nasopharyngeal Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Oropharyngeal Neoplasms
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Nasopharyngeal Cancinoma (NPC)
1
Mouth Neoplasms
1
Lymphoma, Follicular
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Astrocytoma
1
Advanced Glioblastoma
1
Interventions
toripalimab
6
Cisplatin
5
130-nm albumin-bound paclitaxel
5
Drug Therapy
4
tislelizumab
3
sintilimab
3
camrelizumab
3
Injections
3
Immune Checkpoint Inhibitors
3
Fluorouracil
3
Carboplatin
3
nedaplatin
2
anlotinib
2
Radiotherapy
2
Paclitaxel
2
Neoadjuvant Therapy
2
Irinotecan
2
Esophagectomy
2
potassium oxonate
1
pembrolizumab
1
lenvatinib
1
ivarmacitinib
1
irinotecan sucrosofate
1
Watchful Waiting
1
Taxes
1
TP protocol
1
S 1 (combination)
1
Radiotherapy, Intensity-Modulated
1
Radiation
1
Observation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Esophageal Squamous Cell Carcinoma
×
Radiotherapy, Intensity-Modulated
×
Clear all
NCT05791136
2023-03-30
TREE
The Central Hospital of Lishui City
Phase 2
Not yet recruiting
30 enrolled